A Randomized, Open-label Study to Investigate the Impact of Bone Marker Feedback on Persistence to Once Monthly Oral Bonviva (Ibandronate) Treatment for Post-menopausal Osteoporosis.
Phase of Trial: Phase IV
Latest Information Update: 15 May 2015
At a glance
- Drugs Ibandronic acid (Primary)
- Indications Postmenopausal osteoporosis
- Focus Therapeutic Use
- Acronyms SUMMIT
- Sponsors Roche
- 01 Jul 2012 Results published in the Joint Bone Spine.
- 21 Oct 2009 Actual end date (Mar 2009) added as reported by ClinicalTrials.gov.
- 02 Dec 2008 Status changed from active, no longer recruiting to completed, based on information from ClinicalTrials.gov.